Daisy Nie serves as the Executive Director of Cell Therapy Analytical Development & Operations at Novartis, where she leverages her extensive expertise in biologics, cell and gene therapy, and quality control to drive innovative solutions in the rapidly evolving field of regenerative medicine. With a...
Daisy Nie serves as the Executive Director of Cell Therapy Analytical Development & Operations at Novartis, where she leverages her extensive expertise in biologics, cell and gene therapy, and quality control to drive innovative solutions in the rapidly evolving field of regenerative medicine. With a robust background in analytical development, Daisy is instrumental in overseeing critical projects that focus on the characterization and validation of cell-based therapies, ensuring that they meet stringent regulatory submissions and quality standards.
Her leadership in key initiatives has significantly advanced Novartis's capabilities in cell culture and molecular cloning, enabling the development of cutting-edge therapies that harness the power of biomarker discovery and protein purification. Daisy's proficiency in qPCR and biochemistry allows her to spearhead research that not only enhances the efficacy of therapeutic candidates but also streamlines the analytical processes necessary for successful product development.
In her role, Daisy collaborates closely with cross-functional teams, fostering a culture of innovation and excellence that is essential for navigating the complexities of cell therapy. Her commitment to quality and operational efficiency ensures that Novartis remains at the forefront of the industry, delivering transformative treatments to patients in need. With a keen focus on advancing scientific knowledge and practical applications, Daisy Nie is a pivotal figure in the landscape of cell and gene therapy, driving impactful change through her strategic vision and technical acumen.
